Methazolamide
Carbonic Anhydrase Inhibitors
- Drug class
- Carbonic Anhydrase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 4
- FDA reports (12 mo)
- 16
Overview
Plain-language summary, compiled from the cited regulatory records
Methazolamide is a medication classified as a carbonic anhydrase inhibitor [1]. It is approved for use in treating certain ocular conditions where reducing intraocular pressure is beneficial [1]. These approved uses include managing chronic open-angle glaucoma and secondary glaucoma [1]. Additionally, methazolamide is indicated for use before surgery in cases of acute angle-closure glaucoma when a reduction in intraocular pressure is desired prior to the procedure [1].
In the past 12 months, there were 16 adverse event reports associated with methazolamide [2]. The most frequently reported reactions in this period included eye pain, clavicle fracture, death, dizziness, and the perception of the drug being ineffective [2]. Methazolamide is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | March 27, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
Methazolamide Tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Methazolamide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 042586b3-4d49-c5… · revised August 30, 2023 [PDF]
- [2]Health Canada (DPD) · 02245882 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.